IGC (IGC Pharma) Payments of Debt: $-0.00 Mil (TTM As of Mar. 2026)


IGC IGC Pharma Inc IGC
30 GF Score
Price $0.28
GF Value $0.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Payments of Debt?

IGC Pharma IGC +2.26% 30 Payments of Debt is $-0.00 Mil as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 30/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

IGC Pharma's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

IGC Pharma's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.

IGC Pharma Payments of Debt Related Terms

IGC Pharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Payments of Debt Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.00 -0.00 -0.00 -0.00

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 0.00
IGC
30GF Score
IGC Pharma Inc IGC
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.00 Mil mean?
IGC Pharma (IGC) has a Payments of Debt of $-0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on IGC Pharma and its competitors.
Is IGC Pharma's Payments of Debt too high?
IGC Pharma's current Payments of Debt is $-0.00 Mil. Overall, IGC Pharma has a GF Score™ of 30/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Payments of Debt compare to SER and NRSN?
IGC Pharma's Payments of Debt of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on IGC Pharma and its competitors. IGC Pharma's current Payments of Debt is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.28 — trading 17% above its estimated fair value. The current Payments of Debt is $-0.00 Mil. IGC Pharma's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For IGC Pharma (IGC), the current Payments of Debt is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.28 is trading 17% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • Payments of Debt: $-0.00 Mil
  • GF Value™: $0.24 vs. price of $0.28 (17% above fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
30GF Score

Get the complete analysis for IGC

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$0.24
GF Value